In this study, only 40% of the included patients received therapy with tamoxifen or aromatase inhibitors, which is lower than expected given that more than two-thirds of breast tumors express estrogen and/or progesterone receptors. The gene discussed is CYP19A1; the disease is breast neoplasm.